Ginkgo biloba is a popular herb that originated from traditional Chinese medicine in ancient times. This herb became popular in Western countries in the last decade due to its amazing properties.

Ginkgo biloba is an herb that has received acclaim as a memory enhancer and anti-aging product. It's now among the ten most popular dietary supplements sold in the United States. Although it has ...

When ginkgo trees begin blooming in Washington, it can mean only one thing: The smell of vomit is not far behind. The female version of the hardy ginkgo tree is best known in cities nationwide for ...

Q. I have read that ginkgo trees can live for hundreds of years. Is this true, and what makes them so unusual? Why are they ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Can Ginkgo Bioworks stage a major comeback? Or is the stock likely to continue floundering? Two Motley Fool contributors make ...

It currently has no long-term debt, though it does have $221.8 million in long-term capital lease obligations. That means it ...

The bad news keeps coming for Ginkgo Bioworks. Four days after it announced it was slashing labor costs by at least 25 percent, the once-high-flying Boston life sciences firm said it had received ...

Ginkgo Bioworks' first quarter earnings were weak, with revenue and guidance falling well short of expectations. The company is shifting its business model away from ownership of IP and ...

The company also wants to terminate and sublease extra space. After a disappointing first quarter earnings, Ginkgo Bioworks Holdings Inc. plans to reduce its labor expenses at least 25% ...

After lackluster first-quarter earnings, Ginkgo Bioworks said it will slash labor expenses by at least 25 percent, which will include an unspecified number of job cuts. Total revenue in the first ...

Ginkgo is embarking on a cost-cutting plan that could pave the path to profitability and share performance. The main bear case against Ginkgo is there's no compelling reason to buy the stock right ...